- Record: found
- Abstract: found
- Article: not found
Mogamulizumab for Treatment of Human T-lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Single-Center US-based Series.
Eric A Meyerowitz
1
,
2 ,
Shibani S Mukerji
3
,
4 ,
G Kyle Harrold
3
,
4 ,
Rachel M Erdil
5 ,
Steven T Chen
4
,
6 ,
Emily A Rudmann
3 ,
Athe Tsibris
4
,
7
,
8 ,
Nagagopal Venna
3
,
4 ,
Gregory K Robbins
4
,
8
Sep 18 2023
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic neurological condition characterized by progressive myelopathic symptoms including spasticity, pain, weakness, and urinary symptoms, without proven treatments. Mogamulizumab (MOG) is a monoclonal antibody that binds CCR4 and leads to the clearance of HTLV-1-infected CCR4+ cells. A phase 1-2a study in Japan evaluated MOG for the treatment of HAM/TSP and reported decreases in HTLV-1 proviral load and neuroinflammatory markers, with clinical improvement in some participants.